For decades, the promise of RNA interference as a cancer therapy has outpaced our ability to deliver it safely — the right molecule to the right cell, without collateral harm. A research team has now brought that promise measurably closer, engineering nanocarriers that use antibodies as molecular addresses to find and enter blood cancer cells within hours, then release gene-silencing payloads that disrupt the very machinery keeping those cells alive. The work does not yet cross the threshold into clinical use, but it narrows a gap that has long separated elegant biology from practical medicine